ABT vs STRO · P/E 25, rev $44.33B vs rev $62.0M
Abbott Laboratories (ABT) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. STRO currently screens at market cap $470.8M.
Not investment advice. Open the ABT and STRO stock pages for the full models.
Not investment advice.